TECHNOLOGY-HOLDINGS
18.6.2024 18:01:29 CEST | Business Wire | Press release
Technology Holdings (TH), a global investment bank with offices in North America, Europe and the Asia-Pacific, with a track record of closing transactions in 24 countries globally, proudly announces the launch of ‘TH Buy and Build’, its specialized Buy Side investment banking division. ‘TH Buy and Build’ serves Strategic Buyers and Private Equity Funds seeking expert guidance and support to navigate the complexities of the acquisition and investment target landscape globally and to close transactions rapidly and efficiently.
“We’re excited to unveil ‘TH Buy and Build', serviced by our dedicated team of buy side investment bankers globally in 11 countries across 4 continents. This launch marks a significant milestone in our mission to deliver exceptional value to strategic buyers through programmatic M&A and to support private equity funds with making investments and executing ‘Buy and Build' strategies for their portfolio companies,” said Vivek Subramanyam, Founder and CEO of Technology Holdings.
This strategic move further solidifies Technology Holdings’ position as a leading global investment bank, offering Sell Side M&A and Buy Side M&A, Growth Equity, Private Equity advisory and Growth Consulting services exclusively to technology services, business process management, consulting, technology and healthcare companies globally.
‘TH Buy and Build' offerings:
- Programmatic M&A: Dedicated support to close multiple acquisitions to rapidly enhance capabilities and reach globally.
- Private Equity ‘Buy & Build’: Support Private Equity Funds in a dedicated manner to make investments and scale portfolio companies through acquisitions globally.
- Bolt-ons & Tuck-ins: Specific acquisition searches to enhance capabilities, market presence, delivery footprint, technology etc.
3 Step Buy Side M&A Process:
Technology Holdings’ 3 step buy side M&A process, defined below, is driven by their sector expertise, global presence, and an in-depth understanding of the acquisition target landscape.
- Create an actionable M&A plan to achieve strategic objectives: Technology Holdings’ team will work closely to develop an enhanced investment thesis and an actionable M&A or investment plan.
- Comprehensive Deal Origination: Comprehensive and iterative target identification and filtering process, leveraging Technology Holdings’ sector insights and market intelligence, to bring a qualified shortlist of targets that meet acquisition objectives.
- Meticulous Deal Execution: Robust transaction execution, leveraging Technology Holdings’ deal execution expertise and process rigor to enhance equity value.
For more information click here or contact the team at THBuyandBuild@technologyholdings.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618324873/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom